Immunomodulatory effects of IL-33 in atopic dermatitis

Investigating Protein Neutralization in Atopic Dermatitis

Recruiting
18 years - 100 years
All
Phase N/A
1 Location

Brief description of study.

The purpose of this study is to define the effects of neutralizing a certain protein affecting healthy and diseased skin and blood from patients with atopic dermatitis and to determine if the response to neutralization will differ between different subtypes of atopic dermatitis

Detailed description of study

The purpose of this study is to define the effects of neutralizing a certain protein (IL-33) affecting healthy and diseased skin and blood from patients with atopic dermatitis and to determine if the response to neutralization will differ between different subtypes of atopic dermatitis.

Participants will be paid for their participation.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: healthy
  • Age: 18 years - 100 years
  • Gender: All

Inclusion Criteria
Active moderate to severe atopic dermatitis (AD) or healthy individuals who are similarly matched to enrolled AD patients in age, race, and sex
Exclusion Criteria
Systemic immunosuppressant in the past 6 months
Use of UVB or UVA phototherapies or tanning beds in the past 3 months
Use of topical steroids in/around biopsy sites >1 (preferably 2) week(s)
History of primary or secondary immunodeficiency disorders/diseases
History of keloid scar formation
History of allergy to lidocaine or other amide local anesthetics
History of bleeding disorders that could result in prolonged bleeding
History of prolonged or poor wound healing

Updated on 19 Feb 2024. Study ID: 1508749599

This study investigates the effects of neutralizing a certain protein in the skin and blood of patients with atopic dermatitis, a condition causing red and itchy skin. The study aims to see if the response to this neutralization differs among various subtypes of atopic dermatitis.

Participants will undergo procedures to assess the effects of protein neutralization. These procedures will help determine differences in response among the subtypes of atopic dermatitis.

  • Who can participate: The study is open to individuals with active moderate to severe atopic dermatitis and healthy individuals matched in age, race, and sex. Key exclusions include recent use of systemic immunosuppressants, phototherapies, or certain topical treatments, and a history of specific medical conditions.
  • Study details: Participants will take part in procedures to neutralize a protein in their skin and blood. A placebo, which is an inactive substance that looks like the investigational medication but does not contain any medicine, may be used.

Find a site

Message sent successfully.
We have submitted the information you provided to the research team at the location you chose. For your records, we have sent a copy of the message to your email address.
If you would like to be informed of other studies that may be of interest to you, you may sign up for Patient Notification Service.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact label
Race
Ethnicity
Other language

Default Content Message Here